Cargando…

Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung

Detalles Bibliográficos
Autores principales:	Jiao, Yuyan, Liu, Ming, Luo, Ningning, Guo, Hao, Li, Jianzhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474472/ https://www.ncbi.nlm.nih.gov/pubmed/34589958 http://dx.doi.org/10.1016/j.jtocrr.2020.100079

Ejemplares similares

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

LGG-36. DESMOPLASTIC INFANTILE GANGLIOGLIOMA (DIG) WITH A PPP1CB-ALK FUSION IN A 6-YEAR-OLD GIRL
por: McDonald, William, et al.
Publicado: (2020)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1‐ALK fusion
por: Yin, Qiang, et al.
Publicado: (2021)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Targeting ALK in Neuroendocrine Tumors of the Lung
por: Akhoundova, Dilara, et al.
Publicado: (2022)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance
por: Wang, Ye, et al.
Publicado: (2019)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
por: Sim, Jongmin, et al.
Publicado: (2018)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
por: Kobayashi, Takayuki, et al.
Publicado: (2023)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

SMPD3‐ALK: A novel ALK fusion gene in lung adenocarcinoma
por: Liang, Yuepei, et al.
Publicado: (2021)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
por: Dacic, Sanja, et al.
Publicado: (2016)

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
por: Yang, Dafu, et al.
Publicado: (2021)

The role of Alk-1 and Alk-5 in the mechanosensing of chondrocytes
por: Sanz-Ramos, Patricia, et al.
Publicado: (2014)

Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report
por: Yorozuya, Takafumi, et al.
Publicado: (2021)

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
por: Ye, Zhifeng, et al.
Publicado: (2023)

Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
por: Urbán, László, et al.
Publicado: (2020)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
por: Mori, Mio, et al.
Publicado: (2019)

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
por: Zeng, Zhu, et al.
Publicado: (2022)

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient
por: Hu, Yijuan, et al.
Publicado: (2019)

Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report
por: Huang, Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7e3m0nh4eqrfdc9i7haod6rkq3